146 related articles for article (PubMed ID: 22789555)
1. Response of cerebral metastasis secondary to prostate cancer to primary androgen suppression.
Bhuva NJ; Ward D; Hughes R
BMJ Case Rep; 2010 Nov; 2010():. PubMed ID: 22789555
[TBL] [Abstract][Full Text] [Related]
2. [Adjuvant or therapeutic androgen suppression in locoregional advanced prostatic carcinoma (RTOG 85-31)].
Hinkelbein W
Strahlenther Onkol; 1998 Jul; 174(7):385-6. PubMed ID: 9689964
[No Abstract] [Full Text] [Related]
3. Phase III radiation therapy oncology group (RTOG) trial 86-10 of androgen deprivation adjuvant to definitive radiotherapy in locally advanced carcinoma of the prostate.
Pilepich MV; Winter K; John MJ; Mesic JB; Sause W; Rubin P; Lawton C; Machtay M; Grignon D
Int J Radiat Oncol Biol Phys; 2001 Aug; 50(5):1243-52. PubMed ID: 11483335
[TBL] [Abstract][Full Text] [Related]
4. Is 6 months of androgen suppression therapy plus radiotherapy of benefit in patients with localized prostate cancer?
Pollack A; Horwitz EM
Nat Clin Pract Oncol; 2005 Jan; 2(1):12-3. PubMed ID: 16264846
[No Abstract] [Full Text] [Related]
5. Phase III trial of androgen suppression using goserelin in unfavorable-prognosis carcinoma of the prostate treated with definitive radiotherapy: report of Radiation Therapy Oncology Group Protocol 85-31.
Pilepich MV; Caplan R; Byhardt RW; Lawton CA; Gallagher MJ; Mesic JB; Hanks GE; Coughlin CT; Porter A; Shipley WU; Grignon D
J Clin Oncol; 1997 Mar; 15(3):1013-21. PubMed ID: 9060541
[TBL] [Abstract][Full Text] [Related]
6. Case records of the Massachusetts General Hospital. Case 16-2011. A 67-year-old man with recurrent prostate cancer.
Smith MR; Zietman AL; Finkelstein JS; Wu CL
N Engl J Med; 2011 May; 364(21):2044-51. PubMed ID: 21612474
[No Abstract] [Full Text] [Related]
7. Androgen suppression adjuvant to definitive radiotherapy in prostate carcinoma--long-term results of phase III RTOG 85-31.
Pilepich MV; Winter K; Lawton CA; Krisch RE; Wolkov HB; Movsas B; Hug EB; Asbell SO; Grignon D
Int J Radiat Oncol Biol Phys; 2005 Apr; 61(5):1285-90. PubMed ID: 15817329
[TBL] [Abstract][Full Text] [Related]
8. A cost-outcome analysis of long-term adjuvant goserelin in addition to radiotherapy for locally advanced prostate cancer.
Samant RS; Dunscombe PB; Roberts GH
Urol Oncol; 2003; 21(3):171-7. PubMed ID: 12810202
[TBL] [Abstract][Full Text] [Related]
9. Treatment of an orchiectomized patient with hormone-refractory prostate cancer with LH-RH agonists.
Damyanov C; Tzingilev B; Tabakov V
Eur Urol; 2001 Oct; 40(4):474-6; discussion 477. PubMed ID: 11713406
[TBL] [Abstract][Full Text] [Related]
10. Use of neoadjuvant and adjuvant therapy to prevent or delay recurrence of prostate cancer in patients undergoing radiation treatment for prostate cancer.
Pisansky TM
Urology; 2003 Dec; 62 Suppl 1():36-45. PubMed ID: 14747040
[TBL] [Abstract][Full Text] [Related]
11. Adjuvant hormone therapy in locally advanced and localized prostate cancer: three EORTC trials.
Bolla M; de Reijke TM; Zurlo A; Collette L
Front Radiat Ther Oncol; 2002; 36():81-6. PubMed ID: 11842758
[No Abstract] [Full Text] [Related]
12. Docetaxel followed by hormone therapy after failure of definitive treatments for clinically localized/locally advanced prostate cancer: preliminary results.
Hussain A; Dawson N; Amin P; Naslund M; Engstrom C; Chen T
Semin Oncol; 2001 Aug; 28(4 Suppl 15):22-31. PubMed ID: 11685725
[TBL] [Abstract][Full Text] [Related]
13. Pulmonary metastases in metastatic prostate cancer: host tissue-tumor cell interactions and response to hormone therapy.
Behrakis P; Koutsilieris M
Anticancer Res; 1997; 17(3A):1517-8. PubMed ID: 9179189
[TBL] [Abstract][Full Text] [Related]
14. Neuroendocrine differentiation of localized prostate cancer during endocrine therapy.
Nemoto K; Tomita Y
Scand J Urol Nephrol; 2007; 41(6):558-60. PubMed ID: 17853028
[TBL] [Abstract][Full Text] [Related]
15. Pseudomyxoma ovariilike posttherapeutic alteration in prostate adenocarcinoma.
Beer TW; Theaker JM; Tulloch DN
J Clin Pathol; 1998 Nov; 51(11):878. PubMed ID: 10193337
[No Abstract] [Full Text] [Related]
16. Does androgen suppression enhance the efficacy of postoperative irradiation? A secondary analysis of RTOG 85-31. Radiation Therapy Oncology Group.
Corn BW; Winter K; Pilepich MV
Urology; 1999 Sep; 54(3):495-502. PubMed ID: 10475361
[TBL] [Abstract][Full Text] [Related]
17. Improved survival in patients with locally advanced prostate cancer treated with radiotherapy and goserelin.
Bolla M; Gonzalez D; Warde P; Dubois JB; Mirimanoff RO; Storme G; Bernier J; Kuten A; Sternberg C; Gil T; Collette L; Pierart M
N Engl J Med; 1997 Jul; 337(5):295-300. PubMed ID: 9233866
[TBL] [Abstract][Full Text] [Related]
18. Cutaneous Metastases From Adenocarcinoma of the Prostate.
Flores-Terry MÁ; Cruz-Conde de Boom R; García-Arpa M; de Lara-Simón IM
Actas Dermosifiliogr (Engl Ed); 2018 May; 109(4):360. PubMed ID: 28823393
[No Abstract] [Full Text] [Related]
19. [Combination of external irradiation and androgen suppression for prostate cancer: facts and questions].
Bolla M; Fourneret P; Beneyton V; Tessier A; Jover F; Verry C
Cancer Radiother; 2010 Oct; 14(6-7):510-4. PubMed ID: 20728391
[TBL] [Abstract][Full Text] [Related]
20. [Predicting long-term survival, and the need for hormonal therapy: a meta-analysis of RTOG prostate cancer trials].
Noël G; Mazeron JJ
Cancer Radiother; 2001 Apr; 5(2):205. PubMed ID: 11355590
[No Abstract] [Full Text] [Related]
[Next] [New Search]
